Portal hypertension and iron depletion in patients with genetic hemochromatosis

Anna Ludovica Fracanzani, Silvia Fargion, Riccardo Romano, Dario Conte, Alberto Piperno, Roberta D'Alba, Clara Mandelli, Mirella Fraquelli, Stefania Pacchetti, Mario Braga, Gemino Fiorelli – 1 October 1995 – Clinically, portal hypertension has been considered to be less common and less severe in patients with cirrhosis resulting from iron overload in homozygotes for genetic hemochromatosis than in patients with cirrhosis of other causes.

Nuclear scaffold‐associated protease: In situ nuclear localization and effects of a protease inhibitor on growth and morphology of a ras‐transformed hepatocyte cell line

Gary A. Clawson, Ling Ren, Harriet C. Isom – 1 October 1995 – We have previously identified a multicatalytic protease (MCP) activity associated with the nuclear scaffold (NS) in hepatocytes and fibroblasts. When we used the chloromethylketone protease inhibitor AAPFcmk, which is targeted to chymotrypsinlike protease activity, we observed a dramatic inhibition of transformation of fibroblasts, with effects that were relatively selective for the NS fraction.

Tyrosine kinase growth factor receptors but not seven‐membrane–spanning receptors or phorbol esters activate mitogen‐activated protein kinase in rat hepatocytes

Pere Ginès, Xiaomei Li, Jeffrey L. Zamarripa, Susan E. S. Brown, Eric D. Wieder, Toshikazu Nakamura, Phillip S. Guzelian, Robert W. Schrier, Lynn E. Heasley, Raphael A. Nemenoff – 1 October 1995 – The response of rat hepatocytes to hormones and growth factors has been extensively studied with respect to phospholipase regulation and calcium mobilization. However, the mitogen‐activated protein (MAP) kinase cascade which integrates signals from a wide variety of extracellular stimuli has not been examined in these cells.

An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection

Cyrille Féray, Didier Samuel, Michèle Gigou, Valérie Paradis, Marie Francoise David, Catherine Lemonnier, Michel Reynès, Henri Bismuth – 1 October 1995 – The aim of this open trial was to assess the efficacy and the safety of interferon (IFN) alfa therapy in liver transplant recipients with chronic active hepatitis caused by hepatitis C virus. In July 1991, among 447 liver recipients regularly observed at our institution, 46 had developed HCV‐related chronic active hepatitis defined by piece meal necrosis.

Oval cell differentiation into hepatocytes in the acetylaminofluorene‐treated regenerating rat liver

Matthew Golding, Catherine E. Sarraf, El‐Nasir Lalani, T. V. Anilkumar, Robert J. Edwards, Peter Nagy, Snorri S. Thorgemsson, Malcolm R. Alison – 1 October 1995 – When hepatocyte regeneration after a two‐thirds partial hepatectomy (PH) in rats is blocked by oral gavage of acetylaminofluorene, a proliferation of ductular cells ensues that results in a profusion of neoductules radiating from each portal tract.

Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture

Jordi Muntané‐Relat, Jean‐Claude Ourlin, Jacques Domergue, Patrick Maurel – 1 October 1995 – We have investigated the effect of cytokines, including interleukin‐6 (Il‐6), interleukin‐1α (Il‐1α), and tumor necrosis factor‐alpha (TNF‐α), on the inducible expression of cytochrome P450s (CYP) CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. The ability of these cultures to mimic the acute phase response when stimulated with cytokines was evaluated using immunoblotting to measure the production of albumin, ferritin, fibrinogen, and ceruloplasmin.

Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B

Yosuke Morimitsu, David E. Kleiner, Hari S. Conjeevaram, Chu Chieh Hsia, Adrian M. Di Bisceglie, Edward Tabor – 1 October 1995 – The effect of interferon alfa (IFN‐α) therapy on the expression of transforming growth factor alpha (TGF‐α) in the liver during chronic hepatitis B was investigated. Serial liver biopsy specimens were evaluated from 35 patients who had participated in a randomized, controlled trial of recombinant human IFN‐α for the treatment of chronic hepatitis B.

Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C

Shirley Coverdale, Karen Byth, Jacqueline Field, Christopher Liddle, Rita Lin, Geoffrey C. Farrell – 1 October 1995 – To determine whether hepatic metabolic function affects the response to interferon treatment, we measured antipyrine clearance (APC) in 85 patients with chronic active hepatitis C and compared the results with treatment outcome.

Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia

Massimo Siciliano, Daniele Tomasello, Alessandro Milani, Bianca Maria Ricerca, Sergio Storti, Lodovico Rossi – 1 October 1995 – Chronic anemia is frequently observed in patients affected by cirrhosis. To investigate the possible role of erythropoietin (Epo) in the pathogenesis of anemia in cirrhosis, we measured the immunoreactive Epo levels and the respective hemoglobin (Hb) concentrations in 48 anemic and nonanemic cirrhotic patients and in a control group of healthy subjects and patients with iron‐deficiency anemia.

Ciprofloxacin and long‐term prevention of spontaneous bacterial peritonitis: Results of a prospective controlled trial

Alain Rolachon, Laurent Cordier, Yannick Bacq, Jean‐Baptiste Nousbaum, Anne Franza, Jean‐Claude Paris, Serge Fratte, Benoit Bohn, Pascal Kitmacher, Jean‐Paul Stahl, Jean‐Pierre Zarski – 1 October 1995 – The aim of this prospective double‐blind study was to evaluate the value of long‐term antibiotic prophylaxis using ciprofloxacin for the prevention of spontaneous bacterial peritonitis (SBP) in 60 cirrhotic patients with low ascitic fluid protein levels (<15 g/L).

Subscribe to